Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Registry for Stage 2 Type 1 Diabetes
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06481904
- Locations
- 🇺🇸
University of Chicago Medical Center- Site Number : 8400017, Chicago, Illinois, United States
🇺🇸Riley Hospital for Children at IU Health- Site Number : 8400004, Indianapolis, Indiana, United States
🇺🇸Norton Healthcare- Site Number : 8400030, Louisville, Kentucky, United States
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: placebo
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT06454240
- Locations
- 🇺🇸
Modena Allergy + Asthma Site Number : 8400005, La Jolla, California, United States
🇺🇸United Gastroenterologists - Murrieta- Site Number : 8400021, Murrieta, California, United States
🇺🇸Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003, Roseville, California, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 166
- Registration Number
- NCT06444451
- Locations
- 🇯🇵
Investigational Site Number : 3920003, Ebina-shi, Kanagawa, Japan
🇯🇵Investigational Site Number : 3920001, Yokohama, Japan
🇯🇵Investigational Site Number : 3920002, Kamiamakusa, Kumamoto, Japan
A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9
- Registration Number
- NCT06418620
- Locations
- 🇺🇸
Prism Research Site Number : 8400001, Saint Paul, Minnesota, United States
A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT06418607
- Locations
- 🇺🇸
Prism Research Site Number : 8400002, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami Site Number : 8400001, Miami, Florida, United States
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06415175
- Locations
- 🇪🇸
Investigational Site Number : 7240003, Barcelona, Spain
🇪🇸Investigational Site Number : 7240001, Madrid, Spain
🇪🇸Investigational Site Number : 7240010, Madrid, Spain
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 961
- Registration Number
- NCT06407934
- Locations
- 🇨🇳
Investigational Site Number : 1560041, Shenyang, China
🇨🇳Investigational Site Number : 1560026, Shenyang, China
🇨🇳Investigational Site Number : 1560064, Shenzhen, China
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
- Conditions
- Chronic Rhinosinusitis With Nasal Polyposis
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06393946
- Locations
- 🇫🇷
Investigational Site Number: 250.0001, Nantes, France
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- Conditions
- Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2500
- Registration Number
- NCT06372145
- Locations
- 🇨🇿
Investigational Site Number : 2030008, Prague, Czechia
🇨🇿Investigational Site Number : 2039906, Prague, Czechia
🇨🇿Investigational Site Number : 2039905, Prague, Czechia
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06356571
- Locations
- 🇺🇸
Smilow Cancer Center at Yale-New Haven- Site Number : 8400020, New Haven, Connecticut, United States
🇺🇸Millennium Oncology- Site Number : 8400011, Pembroke Pines, Florida, United States
🇺🇸BRCR Global- Site Number : 8400008, Plantation, Florida, United States